Nasdaq

FDA Accepts for Priority Review Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License ...
Reuters

EU approves Sanofi's Dupixent for 'smoker's lungs'

July 3 (Reuters) - Sanofi (SASY.PA), opens new tab and partner Regeneron (REGN.O), opens new tab on Wednesday won European Union approval for wider use of their Dupixent injection in patients with a ...
Nasdaq

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly ...
Hosted on MSN

Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays Dull

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on Friday announced that the U.S. Food and Drug Administration (FDA) has approved their Dupixent injection for the treatment of adult patients ...

Sanofi 'Strong Buy': Continued Dupxient Sales Growth And Sarclisa OBI First

Sanofi looks compelling with strong fundamentals and a robust pipeline. Click for this updated look at SNY stock and why I ...
Yahoo

Sanofi's Dupixent wins U.S. approval for bigger use

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Sanofi logo at the company's headquarters during the annual results news conference in Paris (Reuters) -Sanofi won ...
FiercePharma

Sanofi's Dupixent puts on another stellar show, and it's still 'at the beginning' of its journey: exec

Five years after its first FDA approval in eczema, Sanofi’s Dupixent is still blazing a trail in inflammatory diseases. That’s the evaluation of Bill Sibold, Sanofi’s global head of specialty care, ...
Business Insider

Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps

Dupixent also met all secondary endpoints in both trials, including demonstrating a significant reduction in the need for systemic corticosteroids or surgery, and improvements in smell and chronic ...
Healio

Dupixent improves atopic dermatitis in young children

Please provide your email address to receive an email when new articles are posted on . Pediatric patients with atopic dermatitis who were treated with Dupixent plus topical corticosteroids had ...
Business Insider

FDA Accepts for Priority Review Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis

Adverse events more commonly observed with Dupixent and TCS included conjunctivitis, nasopharyngitis and injection site reactions, which is consistent with the previously documented safety profile of ...
Reuters

Sanofi's Dupixent wins U.S. approval for bigger use

May 20 (Reuters) - Sanofi (SASY.PA), opens new tab won expanded U.S. approval for its best-selling Dupixent injection to treat an allergic inflammation of the esophagus, the Food and Drug ...